Interpersonal Psychotherapy for Severely Depressed Inpatients
Information source: German Research Foundation
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Major Depression
Intervention: Interpersonal Psychotherapy (Behavioral); sertraline or amitriptyline (Drug)
Phase: N/A
Status: Terminated
Sponsored by: German Research Foundation Official(s) and/or principal investigator(s): Mathias Berger, MD, Study Director, Affiliation: University Clinic Freiburg, Dept. of Psychiatry and Psychotherapy
Summary
We examined the hypotheses that severely depressed inpatients treated for 5 weeks with IPT-S
plus pharmacotherapy have 1) a higher reduction in depressive symptoms and 2) higher
response- and remission rates compared to pharmacotherapy plus CM. For the follow-up period
(12 months) we hypothesized a better symptomatic and psychosocial longterm outcome and lower
rates of relapse for patients initially treated with combination therapy.
Clinical Details
Official title: An Intensive Treatment Program of Interpersonal Psychotherapy Plus Pharmacotherapy for Severely Depressed Inpatients
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The 17-item version of the Hamilton Rating Scale for Depression (HAMD) served as the primary outcome measure
Secondary outcome: Beck Depression Inventory
Detailed description:
A randomized controlled trial was conducted in 124 hospitalized patients with a DSM IV
diagnosis of Major Depressive Disorder comparing 5 weeks of Interpersonal Psychotherapy
modified for depressed inpatients (IPT-S) plus pharmacotherapy versus medication plus
intensive Clinical Management (CM). The study included a prospective, naturalistic follow-up
3- and 12 months after acute treatment in 97 of 105 treatment completers. The 17-item
version of the Hamilton Rating Scale for Depression (HAMD) served as the primary outcome
measure.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Major Depression (single episode, recurrent or bipolar II) according to the Structured
Clinical Interview for DSM IV (SCID)and a score of ≥ 16 on the 17-item version of the
Hamilton Rating Scale for Depression (HAMD)
Exclusion Criteria:
(1) concurrent diagnosis of bipolar I disorder, primary substance abuse or dependency,
mental disorder due to organic factors, and borderline or antisocial personality disorder,
(2) psychotic symptoms, (3) severe cognitive impairment, (4) contraindications to the
study medication, and (5) being actively suicidal
Locations and Contacts
University Clinic Freiburg , Dept. of Psychiatry and Psychotherapy, Freiburg 79104, Germany
Additional Information
Starting date: November 2000
Last updated: December 19, 2006
|